South Korean biopharmaceutical company GC Pharma (KRX:006280) revealed on Thursday that it has submitted its Biologics License Application (BLA) for GC5107 (Immune Globulin Intravenous (Human), 10% Liquid) to the US Food and Drug Administration (FDA).
The company demonstrated positive results in a Phase III study in North America, meeting its primary efficacy endpoint for acute serious bacterial infections (SBI). In trials with PI (Primary Humoral Immunodeficiency) patients, all primary efficacy and safety endpoints corresponding to FDA guidelines were satisfied.
In terms of efficacy, the frequency of SBI was 0.02 for 12 months, satisfying the FDA guidance requirement of no more than one acute serious bacterial infection per person-year. The proportion of infusions with one or more infusion-related AEs was less than 40%.
Following the submission, the FDA has a 60-day filing review period to determine whether the BLA for GC5107 is complete and acceptable for filing.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients